Everolimus induces Met inactivation by disrupting the FKBP12/Met complex

Inhibition of the mechanistic target of rapamycin (mTOR) is a promising treatment strategy for several cancer types. Rapamycin derivatives such as everolimus are allosteric mTOR inhibitors acting through interaction with the intracellular immunophilin FKBP12, a prolyl isomerase with different cellul...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Raimondo, Lucia, D'Amato, Valentina, Servetto, Alberto, Rosa, Roberta, Marciano, Roberta, Formisano, Luigi, Mauro, Concetta Di, Orsini, Roberta Clara, Cascetta, Priscilla, Ciciola, Paola, De Maio, Ana Paula, Di Renzo, Maria Flavia, Cosconati, Sandro, Bruno, Agostino, Randazzo, Antonio, Napolitano, Filomena, Montuori, Nunzia, Veneziani, Bianca Maria, Placido, Sabino De, Bianco, Roberto
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2016
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5129993/
https://ncbi.nlm.nih.gov/pubmed/27223077
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.9484
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares